Oncology medication safety: a 3D status report 2008.
BACKGROUND
The safe use of medications is a major concern in oncology practice. Three organizations collaborated on a survey to determine if practitioners had implemented current recommended safe practices for IV vincristine administration, general oncology safe practices, and safe practices for oral chemotherapy.


METHODS
A survey was distributed to members of the Hematology Oncology Pharmacy Association (HOPA) and the International Society of Pharmacy Practitioners (ISOPP) using Survey Monkey. The Institute of Safe Medication Practices (ISMP) also solicited readers of its Medication Safety Alert! to respond to the survey. A comparison to results from a survey conducted by ISMP in 2006 on safe practices for IV vincristine was also conducted.


RESULTS
The majority of respondents were aware of the WHO recommendations for IV vincristine, although the rate of implementation of the guidelines ranged from 24.1 to 53.6%. When compared to the ISMP 2006 survey there was a 25.8-37.4% improvement in following many of the safe practice guidelines. Administering IV vincristine via a minibag showed the lowest rate of adoption (less than 40%). Of the 35 survey items on general chemotherapy safety strategies, 80% of respondents had implemented at least 21 items in the survey. Overall 32.4% of respondents did not consider oral chemotherapy as requiring the same safety concerns as parenteral therapy.


CONCLUSIONS
The results of this survey will provide a new baseline for the adoption rate of safe medication practice recommendations related to oncology. Further work on addressing barriers in adopting identified safe practice recommendations needs to be conducted.
Johnson
Philip E
PE
Moffitt Cancer Center, Tampa, FL, USA. phil.johnson@moffitt.org
Chambers
Carole R
CR
Vaida
Allen J
AJ
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003625:Data Collection; D064420:Drug-Related Side Effects and Adverse Reactions; D019983:Guideline Adherence / Q000706:statistics & numerical data; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D008508:Medication Errors / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects; D014944:World Health Organization
D000970:Antineoplastic Agents; D014750:Vincristine